Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (Q59571527)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 October 2015

Language	Label	Description	Also known as
English	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial	scientific article published on 22 October 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Dror Michaelson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

7

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

16

object named as

Corina Dutcus

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

author name string

Thomas E Hutson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Hilary Glen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ana Molina

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Timothy Eisen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jakub Zolnierek

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jose Pablo Maroto

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Begoña Mellado

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Bohuslav Melichar

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jiri Tomasek

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Alton Kremer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Han-Joo Kim

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Karen Wood

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

James Larkin

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

22 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1473-1482

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

EAU guidelines on renal cell carcinoma: 2014 update.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00290-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59571527&oldid=2221137158"